Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
22 NC counties and 1 VA county are under alert, including Nash, Halifax, Edgecombe, and Mecklenburg, VA counties.
Just In
Tornado warning: Nash, Edgecombe, Halifax counties under tornado warning until 5:30 p.m. Storm will be near Rocky Mount at 4:45, Tarboro at 4:50
Program
On WRAL at 5: Cellphone connections eliminated by Helene. How providers are helping customers get back online and in touch with loved ones
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Viridian Therapeutics Inc
(NQ:
VRDN
)
22.75
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
146
Open
22.75
Bid (Size)
23.43 (1)
Ask (Size)
23.73 (1)
Prev. Close
22.75
Today's Range
22.75 - 22.75
52wk Range
10.93 - 24.18
Shares Outstanding
9,587,155
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
September 26, 2024
Via
Benzinga
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
September 11, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Performance
YTD
+1.79%
+1.79%
1 Month
+57.22%
+57.22%
3 Month
+72.22%
+72.22%
6 Month
+31.81%
+31.81%
1 Year
+55.82%
+55.82%
More News
Read More
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
September 10, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
September 10, 2024
Via
Benzinga
Decoding 6 Analyst Evaluations For Viridian Therapeutics
August 15, 2024
Via
Benzinga
Expert Ratings For Viridian Therapeutics
July 16, 2024
Via
Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
September 10, 2024
Via
Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
September 10, 2024
Via
Investor's Business Daily
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
September 10, 2024
Via
Benzinga
Exposures
Product Safety
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
September 10, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
7 Analysts Assess Viridian Therapeutics: What You Need To Know
June 06, 2024
Via
Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
September 10, 2024
Via
Benzinga
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
September 09, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Top 3 Health Care Stocks You May Want To Dump This Quarter
July 30, 2024
Via
Benzinga
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
July 25, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Via
Investor's Business Daily
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
Via
InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 11, 2024
Via
Benzinga
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
June 11, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.